Business
£7.05m total gross proceeds from Fundraise
Renalytix PLC announced the successful completion of its fundraise, generating total gross proceeds of approximately £7.05 million, equivalent to $9.5 million. This was achieved through an oversubscribed WRAP Retail Offer, which raised approximately £0.8 million via the issue of 8,421,052 new Ordinary Shares at a price of 9.5 pence per share. This was combined with the previously announced oversubscribed Placing, Subscription, and Additional Subscription, which involved the Placing and Subscription of 54,741,582 shares and 11,000,000 Additional Subscription Shares. Applications have been made for admission of these shares to trading on the AIM Market of the London Stock Exchange, with admission occurring on September 26 and 29, 2025. Disclaimer*
About this update from Renalytix Plc
[{"type":"text","content":"\n\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\n \nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF THE LAWS OF ENGLAND AND WALES PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"UK MAR\"). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE WITHIN THE PUBLIC DOMAIN.\n \nRenalytix plc\n \n(\"Renalytix\" or the \"Company\")\n \n£7.05m total gross proceeds from Fundraise\n \nOversubscribed WRAP Offer, combines with Placing and Subscription, and Additional Subscription \n \nLONDON and NEW YORK, 26 September 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, confirms, further to the announcements made on 22 September, the result of its Fundraise at the Issue Price of 9.5 pence per share. The Company announces that it has raised aggregate gross proceeds of approximately £0.8 million pursuant to a significantly oversubscribed WRAP Retail Offer, alongside the previously announced oversubscribed Placing, Subscription and Additional Subscription. Accordingly, the Company will issue a total of 8,421,052 new Ordinary Shares at the Issue Price pursuant to the WRAP Retail Offer (the \"Retail Offer Shares\").\n \nIn total, the Placing and Subscription, the Additional Subscription and the WRAP Retail Offer have raised gross proceeds of approximately £7.05 million ($9.5 million) for the Company, via the Placing and Subscription of 54,741,582 Placing and Subscription Shares, 11,000,000 Additional Subscription Shares and the 8,421,052 WRAP Retail Offer Shares.\n \nJames McCullough, CEO of Renalytix, commented: \"I would like to thank our investors for a significantly oversubscribed fundraise ...